Integrating Molecular Subtype and CD8 T Cells Infiltration to Predict Treatment Response and Survival in Muscle-invasive Bladder Cancer

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2024 Mar 2

PMID 38430246

Authors

Bingyu Li

Kaifeng Jin

Zhaopei Liu

Xiaohe Su

Ziyue Xu

Ge Liu

Jingtong Xu

Hailong Liu

Yuan Chang

Yiwei Wang

Yu Zhu

Zewei Wang

Le Xu

Weijuan Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Luminal and Basal are the primary intrinsic subtypes of muscle-invasive bladder cancer (MIBC). The presence of CD8 T cells infiltration holds significant immunological relevance, potentially influencing the efficacy of antitumor responses. This study aims to synergize the influence of molecular subtypes and CD8 T cells infiltration in MIBC.

Methods: This study included 889 patients with MIBC from Zhongshan Hospital, The Cancer Genome Atlas, IMvigor210 and NCT03179943 cohorts. We classified the patients into four distinct groups, based on the interplay of molecular subtypes and CD8 T cells and probed into the clinical implications of these subgroups in MIBC.

Results: Among patients with Luminal-CD8T tumors, the confluence of elevated tumor mutational burden and PD-L1 expression correlated with a heightened potential for positive responses to immunotherapy. In contrast, patients featured by Luminal-CD8T displayed a proclivity for deriving clinical advantages from innovative targeted interventions. The Basal-CD8T subgroup exhibited the least favorable three-year overall survival outcome, whereas their Basal-CD8T counterparts exhibited a heightened responsiveness to chemotherapy.

Conclusions: We emphasized the significant role of immune-molecular subtypes in shaping therapeutic approaches for MIBC. This insight establishes a foundation to refine the process of selecting subtype-specific treatments, thereby advancing personalized interventions for patients.

Citing Articles

Sheng H, Gu J, Huang Y, Kolat D, Shi G, Yan L Transl Androl Urol. 2024; 13(10):2280-2293.

PMID: 39507864 PMC: 11535731. DOI: 10.21037/tau-24-456.

Tumor hypoxia in immune infiltration and prognosis of bladder cancer.

Xu F, Yao X, Zhou N, Hu Z, Guo C, Zhou H Transl Cancer Res. 2024; 13(7):3273-3284.

PMID: 39145090 PMC: 11319943. DOI: 10.21037/tcr-23-2375.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Sanli O, Dobruch J, Knowles M, Burger M, Alemozaffar M, Nielsen M . Bladder cancer. Nat Rev Dis Primers. 2017; 3:17022. DOI: 10.1038/nrdp.2017.22. View

Cathomas R, Lorch A, Bruins H, Comperat E, Cowan N, Efstathiou J . The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. Eur Urol. 2021; 81(1):95-103. DOI: 10.1016/j.eururo.2021.09.026. View

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

Damrauer J, Hoadley K, Chism D, Fan C, Tiganelli C, Wobker S . Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A. 2014; 111(8):3110-5. PMC: 3939870. DOI: 10.1073/pnas.1318376111. View

Choi W, Porten S, Kim S, Willis D, Plimack E, Hoffman-Censits J . Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014; 25(2):152-65. PMC: 4011497. DOI: 10.1016/j.ccr.2014.01.009. View

Balar A, Galsky M, Rosenberg J, Powles T, Petrylak D, Bellmunt J . Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 389(10064):67-76. PMC: 5568632. DOI: 10.1016/S0140-6736(16)32455-2. View

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

Zitvogel L, Kepp O, Kroemer G . Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011; 8(3):151-60. DOI: 10.1038/nrclinonc.2010.223. View

10.

Rahim M, Okholm T, Jones K, McCarthy E, Liu C, Yee J . Dynamic CD8 T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell. 2023; 186(6):1127-1143.e18. PMC: 10348701. DOI: 10.1016/j.cell.2023.02.021. View

11.

Jin K, Yu Y, Zeng H, Liu Z, You R, Zhang H . CD103CD8 tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer. Br J Cancer. 2022; 126(11):1581-1588. PMC: 9130137. DOI: 10.1038/s41416-022-01725-6. View

12.

Liu Q, Tian Y, Li Y, Zhang W, Cai W, Liu Y . In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma. J Immunother Cancer. 2020; 8(2). PMC: 7745518. DOI: 10.1136/jitc-2020-001748. View

13.

Huang Q, Zhou Q, Zhang H, Liu Z, Zeng H, Chen Y . Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5 CD8 T cell abundance. Oncoimmunology. 2020; 9(1):1810489. PMC: 7470185. DOI: 10.1080/2162402X.2020.1810489. View

14.

Witjes J, Bruins H, Cathomas R, Comperat E, Cowan N, Gakis G . European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. 2020; 79(1):82-104. DOI: 10.1016/j.eururo.2020.03.055. View

15.

Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O . Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021; 39(6):845-865.e7. DOI: 10.1016/j.ccell.2021.04.014. View

16.

Wherry E, Ha S, Kaech S, Nicholas Haining W, Sarkar S, Kalia V . Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007; 27(4):670-84. DOI: 10.1016/j.immuni.2007.09.006. View

17.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman D . IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017; 127(8):2930-2940. PMC: 5531419. DOI: 10.1172/JCI91190. View

18.

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

19.

Barbie D, Tamayo P, Boehm J, Kim S, Moody S, Dunn I . Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009; 462(7269):108-12. PMC: 2783335. DOI: 10.1038/nature08460. View

20.

Zeng H, Liu Z, Wang Z, Zhou Q, Qi Y, Chen Y . Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses. Int J Cancer. 2019; 146(2):542-552. DOI: 10.1002/ijc.32715. View